In a recent study, a conjugate consisting of an anti-Nectin 4 antibody (clone Enfbio) and IR700 effectively killed luminal bladder cancer cells in vitro, suppressed tumor growth, improved survival in multiple xenograft models, and enabled tumor imaging, demonstrating strong potential as a treatment for luminal subtype bladder cancer [36]. The gene discussed is NECTIN4; the disease is urinary bladder cancer.